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Abstract
Adenosine is a neuromodulator that operates via the most abundant inhibitory adenosine A1 receptors (A1Rs) and the less
abundant, but widespread, facilitatory A2ARs. It is commonly assumed that A1Rs play a key role in neuroprotection since
they decrease glutamate release and hyperpolarize neurons. In fact, A1R activation at the onset of neuronal injury
attenuates brain damage, whereas its blockade exacerbates damage in adult animals. However, there is a down-regulation
of central A1Rs in chronic noxious situations. In contrast, A2ARs are up-regulated in noxious brain conditions and their
blockade confers robust brain neuroprotection in adult animals. The brain neuroprotective effect of A2AR antagonists is
maintained in chronic noxious brain conditions without observable peripheral effects, thus justifying the interest of A2AR
antagonists as novel protective agents in neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease,
ischemic brain damage and epilepsy. The greater interest of A2AR blockade compared to A1R activation does not mean
that A1R activation is irrelevant for a neuroprotective strategy. In fact, it is proposed that coupling A2AR antagonists with
strategies aimed at bursting the levels of extracellular adenosine (by inhibiting adenosine kinase) to activate A1Rs might
constitute the more robust brain neuroprotective strategy based on the adenosine neuromodulatory system. This strategy
should be useful in adult animals and especially in the elderly (where brain pathologies are prevalent) but is not valid for
fetus or newborns where the impact of adenosine receptors on brain damage is different.
Abbreviations: Ab – b-amyloid peptide; A1Rs – A1 receptors; A2ARs – A2A receptors; CGS 21680 – 2-[4-(2-P-carboxy-
ethyl)phenylamino]-50-N-ethylcarboxamidoadenosine; CGS 15943 – 9-chloro-2-(2-furyl)(1,2,4)triazolo(1,5-c)quinazolin-5-
amine; CPA – N6-cyclopenthyladenosine; CSC – 8-(3-chlorostyryl)caffeine; DMPX – 3,7-dimethyl-1-propargylxanthine;
DPCPX – 1,3-dipropyl-8-cyclopentyladenosine; KW6002 – (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-
1H-purine-2,6-dione; MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SCH 58261 – 7-(2-phenylethyl)-5-amino-2-(2-
furyl)-pyrazolo-(4,3-e(-1,2,4-triazolo(1,5-c(pyrimidine; ZM 241385 – 4-(2-{7-amino-2(2-furyl)[1,2,4]triazolo[2,3-a]
[1,3,5]triazin-5-ylamino]ethyl)phenol
Introduction
Adenosine is a purine nucleoside that exists in all cells,
where it is a metabolite involved in key pathways of primary
metabolism such as nucleotide and nucleoside metabolism,
sulphur-containing amino acid metabolism, trans-methyla-
tion reactions and handling of ammonia. Its intra-cellular
concentration in basal conditions is typically around 10Y50
nM in the cell types where it was so far quantified
(reviewed in Cunha [1]). This intracellular concentration
of adenosine is tightly linked to the energy charge of the
cells, in the sense that small decreases in the energy charge
(sometimes considered equivalent to the concentration of
ATP) cause a disproportionate larger increase in the
intracellular levels of adenosine (reviewed in Cunha [1]).
The impact of changes in the intracellular levels of
adenosine on the primary metabolism has not yet been
explored. However, because all cell types so far investi-
gated possess bi-directional non-concentrative nucleoside
transporters, the intracellular levels of adenosine equili-
brate with the extracellular levels of adenosine. Thus, if the
levels of intracellular adenosine rise in a particular cell, a
gradient of increased levels of extracellular adenosine will
build-up in the surroundings of this cell. This extracellular
adenosine is then able to act on metabotropic adenosine
receptors located in the cell membrane of neighbouring
cells (as well as of the cell that released adenosine). The
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activation of the different types of adenosine receptors
(reviewed in the section BAdenosine receptors^) can then
modify cell metabolism according to the set-up of adenosine
receptors and to the primary metabolism of each particular
cell type. In general, most mammalian cell types are equipped
with adenosine A1 receptors (A1Rs), whose activation
causes a decrease in the rate of metabolism, allowing the
cell to cope better with noxious stimuli. Thus, adenosine
fulfils an homeostatic role in most cell types (see [2]),
whereas a noxious stimuli reaching a particular cell causes
a slight drop in energy charge that is converted into a large
change in the intracellular levels of adenosine that diffuses
out of the cell and signals to neighbouring cells via A1Rs
the presence of a noxious stimuli, preparing neighbouring
cells to handle better this noxious stimuli (by generally
decreasing their rate of metabolism).
This review will concentrate on the role of adenosine in
the realm of neuroprotection, focusing on the brain. It
should be kept in mind that the homeostatic role of
adenosine described above occurs in the brain as it occurs
in most mammalian tissues. But adenosine fulfils other
particular roles in the brain, apart from its general
homeostatic role. In fact, the brain is the tissue by far with
the greatest density of the most abundant adenosine A1Rs,
which play key roles in controlling neuronal excitability
and in particular neurotransmitter release, as will be
discussed in the section BModulatory roles of adenosine.^
And several lines of evidence (reviewed in Cunha [1])
indicate that this particular neuromodulatory role of
adenosine is independent of changes in the energy charge
of brain cells, i.e. the neuromodulatory role of adenosine is
independent of the homeostatic role of adenosine.
It is important to emphasise that adenosine behaves as a
typical neuromodulator in the brain. In fact, adenosine
signalling is designed to control the flow of information
between neurons in the brain, rather than to directly
transfer information between neurons, as occurs for neuro-
transmitters. And in contrast to typical neurotransmitters,
there is no evidence available (well on the contrary) for an
accumulation of adenosine in synaptic vesicles or for a
release of adenosine in a quantal manner. However, as
shall be discussed in the section BGeneration of extracel-
lular adenosine,^ the build-up of extracellular adenosine in
synapses is closely connected with the release of neuro-
transmitters and is tightly linked to the frequency and
intensity of neuronal firing.
Adenosine receptors
There are four types of membrane-bound adenosine recep-
tors, named A1, A2A, A2B and A3 receptors. These receptors
have been cloned in different species and are all seven
membrane-spanning metabotropic receptors that have, so
far (but see [3]), been shown to couple via G proteins
(reviewed in [4]). Traditionally, adenosine receptors were
divided into two broad groups: A1Rs and A3Rs that would
negatively couple to adenylate cyclase and A2ARs and
A2BRs that would positively couple to adenylate cyclase.
However, this classification is now difficult to accept
because all adenosine receptors have been shown to couple
to different G proteins and to different transducing systems
in different cell types. Thus, it appears that all adenosine
receptors are fundamentally pleiotropic receptors, i.e. recep-
tors with the potential to couple to different G proteins and to
different transducing systems according to their degree of
activation and with their particular cellular and sub-cellular
localization. It is important to emphasise that the long-time
assumed relation between brain adenosine receptors and
cAMP is mostly of historical interest. For instance, the more
widespread effect of adenosine in the brain (inhibition of
neurotransmitter release by the most abundant A1Rs) is now
well established to be independent of the control of cAMP
levels. This obviously does not exclude that some effects of
adenosine receptors in the brain are actually mediated by
cAMP, in particular important effects of adenosine like the
A1R-mediated neuronal hyperpolarization or A2AR-medi-
ated signal integration in striato-pallidal neurons.
Out of the four adenosine receptors, the A1R is the most
abundant and widespread in the brain (see, e.g., [5]).
A2ARs are concentrated in the basal ganglia (reviewed in
[6]), but they are also present throughout the brain albeit
with a considerably lower density (discussed in BModulatory
roles ofadenosine^).For these two main adenosine receptor
subtypes, there are now good pharmacological tools as
well as receptor knockout mice strains to probe their role
in the brain. Thus, the role of A1Rs is explored taking
advantage of the selectivity of agonists such as CPA and
antagonists such as DPCPX, whereas the role of A2ARs has
been investigated based on the use of its selective antagonist
SCH 58261 (and also other less selective antagonists such as
ZM 241385, CSC or KW6002). Activation of A2ARs can
be achieved with its agonist CGS 21680 but care is
required to exclude the involvement of A1Rs to which
CGS 21680 also binds [7, 8] and activates (e.g., [9]).
Because of their low abundance in the brain, the role of
A2BRs and A3Rs has received considerably less attention.
Thus, the role of adenosine in the brain is currently
considered to be mediated by a balanced activation of A1
and A2A receptors, as shall be detailed in this review. It is
hoped that greater experimental efforts as well as novel
tools will allow a novel perspective on the eventual
relevance of the less abundant A2BRs and A3Rs.
It is also relevant to mention that the traditional idea of
A1Rs and A2ARs as individual signalling systems may also
need to be revised. As illustrated in Figure 1, molecular
studies have opened the possibility of conceiving novel
entities involving adenosine receptors, which may either be
homodimers of either A1Rs [10] or A2ARs [11] or hetero-
dimers. The heterodimers so far identified can involve
A1Rs with either P2Y1Rs (a metabotropic receptor for
ATP) [12] or metabotropic glutamate type 1 receptors [13]
as well as A2ARs with either dopamine D2Rs [14] or
metabotropic glutamate type 5 receptors [15, 16]. Although
the functional relevance of most of these dimers involving
adenosine receptors remains to be determined, this notion
of receptor dimerization clearly wideness the possible
impact of adenosine on brain function and demands a re-
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evaluation of our current pharmacological classification of
adenosine receptor-mediated effects.
Subcellular localization of adenosine receptors
Although A1Rs, and also A2ARs, are widespread in the
brain, they are not homogeneously located in neurons and
other cell types in the brain. Thus, the investigation of their
cellular and subcellular localization may provide a first
insight on the possible modulatory role(s) that may be
fulfilled by adenosine in the brain.
Although A1Rs are most abundant in limbic and neo-
cortical regions, they are also abundant in the basal ganglia
and cerebellum and are also present in most nuclei in the
diencephalon and brain stem (see [5] for a detailed
mapping of the relative densities of brain A1Rs). A1Rs
are considerably more abundant in neurons, but they are
also present in astrocytes [17], microglia [18] and oligo-
dendrocytes [19], albeit with a much lower density. The
localization of A1Rs in neurons is also highly asymmetric.
Immunohistochemical studies of A1R localization in brain
preparations mostly concluded that A1Rs displayed a
predominant axonal localization (see [20]). This probably
reflects the general low accessibility of antibodies to
extracellular epitopes located in the synaptic cleft, which
is densely packed with adhesion molecules [21]. In fact,
when using radioligands or antibodies following cellular
fractionation, it is concluded that A1Rs are most abundant
in synapses [22], in particular in the presynaptic active
zone and post-synaptic density [23]. Functional data also
indicate that the efficiency of A1R activation (and probably
A1R density) is also different amongst different types of
nerve terminals. In fact, A1Rs efficiently control the
release of glutamate, acetylcholine and serotonin, but
several studies have documented the inability of A1Rs to
modulate the release of GABA and of noradrenaline in the
brain (reviewed in [1]). This leads to the idea (detailed in
BModulatory roles of adenosine^) that A1Rs mainly fulfil a
synaptic neuromodulatory role in particular in excitatory
nerve terminals in the brain.
In contrast to the widespread distribution of A1Rs in the
brain, A2ARs are highly concentrated in the basal ganglia
(reviewed in [24]), where their density is about 20 times
greater than elsewhere in the brain [7]. In the basal ganglia,
A2ARs are predominantly located in dendritic spines [25]
and post-synaptic densities [26] of asymmetric contacts
between cortico-thalamic glutamatergic projections and
medium spiny GABAergic neurons, as well as symmetric
contacts between medium spiny neurons (see [25, 27]). In
fact, striatal A2ARs are almost segregated to a particular
sub-type of medium spiny neurons, the enkephalin-con-
taining medium spiny neurons that constitute the indirect
pathway (see [24]), where they are located post-synapti-
cally controlling the integration of signal responses in these
neurons (see reviews in [6, 24, 28]). This high density of
striatal A2ARs has lead to the erroneous idea that A2ARs
were exclusively located in the basal ganglia. However,
both in situ hybridization [29], binding [7], immunological
[30, 31] and functional studies [31, 32] have concurred to
the conclusion that A2ARs are located in limbic and neo-
cortical regions in the brain. And in these regions, A2ARs
have a localization fundamentally different from that found
in the striatum. In fact, cortical A2ARs are predominantly
located in synapses, in particular in the presynaptic active
zone [33]. And as discussed in BModulatory roles of
adenosine,^ this localization of A2ARs is in agreement with
the predominant role of extra-striatal A2ARs in the control
of the release of neurotransmitters (reviewed in [1]). Again,
in contrast to A1Rs, A2ARs seem to have a broader
localization (although at a considerably lower density) in
different types of nerve terminals. In fact, extra-striatal
A2ARs can not only control the release of glutamate (e.g.,
[32]), acetylcholine (e.g., [30, 34Y36]), but can also control
the release of GABA [37] and of noradrenaline [38], which
are mostly insensitive to A1R activation. Apart from their
presynaptic localization, A2ARs are also located in astro-
cytes [39, 40] and microglia cells [41, 42] as well as in
brain blood vessels [43, 44], most likely in endothelial
cells.
In conclusion, throughout the brain, there is predominant
synaptic localization of both A1 and A2A receptors. Both
A1Rs and A2ARs are mostly located presynaptically and
A1Rs also have a dense post-synaptic localization. The
striatum is clearly the exception, where A2ARs are most
densely located post-synaptically. Apart from this predom-
inant neuronal localization, both A1Rs and A2ARs are also
located in astrocytes and microglia and A1Rs are located in
oligodendrocytes and A2ARs in blood vessels.
The rest of the review will mostly concentrate on the
role of A1 and A2A receptors in mediating the effects of
adenosine in the brain. In fact, because of the lack of
selective pharmacological tools and of their low density in
the brain, the possible roles of A3Rs and A2BRs in the brain
are still largely unexplored. However, it should always be
kept in mind that both A3Rs and A2BRs are also present in
the brain. Thus, the presence of A3Rs has been defined in
neurons, both with binding [45], immunological [46] and
functional studies [47, 48] but their function seems more
evident in astrocytes (e.g., [49]) and eventually in micro-
glia [50]. With respect to A2BRs, they are not present in
microglia [50] but are mainly located in astrocytes (e.g.,
[51]). Some functional studies also indicate their possible
presence in neurons (e.g., [52]) although molecular
evidences for their neuronal location are still lacking.
Modulatory roles of adenosine
As inferred from the presentation made on the localization
of adenosine receptors, it is expectable that the main effect
of adenosine on brain function might be a presynaptic
control of the release of neurotransmitters. Also, based on
the considerably greater density of A1Rs compared to other
adenosine receptor subtypes in the brain (excepting the
basal ganglia), it is also expectable that the predominant
effect of adenosine in the brain might be an inhibition of
neurotransmitter release. And, in accordance with these
Adenosine and neuroprotection 113
predictions, electrophysiological studies of the role of
adenosine in brain slices have concluded that adenosine
mainly inhibits neuronal excitability and synaptic trans-
mission (reviewed in [53Y55]). This inhibitory effect of
adenosine is mediated by A1Rs and, accordingly, adeno-
sine is nearly devoid of effects of synaptic transmission
and neuronal excitability in brain slices in the A1R knockout
mice [56].
The adenosine A1R-mediated inhibition of neuronal
excitability and synaptic transmission is a dual role exerted
in different neuronal compartments, both concurring to
refrain neuronal activity. In fact, A1R activation inhibits
excitatory synaptic transmission, mostly through a presyn-
aptic inhibition of glutamate release [57, 58]. This tonic
presynaptic control by A1Rs has recently been shown to be
a key factor in defining the release probability of different
hippocampal synapses [59]. In parallel, A1R activation also
inhibits potassium conductances at the postsynaptic level,
leading to neuronal hyperpolarization (reviewed in [55]).
This latter effect is of uppermost importance to control the
bursting of neuronal firing, but has a minor importance for
the control of synaptic transmission at lower frequencies of
nerve stimulation (see [58]). However, it has been ques-
tioned whether the A1R-mediated inhibition of glutamate
release (which appears to be the predominant action of
adenosine at lower frequencies of nerve stimulation) might
be of relevance for the control of neuronal firing at higher
frequencies of nerve stimulation (see [60]). The high
density of A1Rs in the post-synaptic density also antici-
pates an important role of adenosine in the control of
signal integration at the post-synaptic level. Accordingly,
the pioneering work of de Mendonc¸a revealed that the
tonic activation of A1Rs controls the amplitude of synaptic
plasticity in excitatory circuits (reviewed in [61]). This
might result from the ability of A1Rs to efficiently control
NMDA receptors [62, 63] as well as post-synaptically
located voltage-sensitive calcium channels [52, 63].
In contrast to these multiple actions of A1Rs to inhibit
neuronal function, our knowledge about the role of A2ARs
in modulating neuronal activity is more limited. This is
Figure 1. Ability of adenosine A2A receptors (A2ARs) to fine-tune the efficiency of functioning of different other modulatory systems operated by either
metabotropic, ionotropic or catalytic receptors. Activation of A2ARs can either inhibit (j) or facilitate (+) the receptors using either protein kinase A
(PKA) or C (PKC) as transducing pathways. Note that this modulation of different systems is a compilation and does not imply that A2ARs affect all
these transducing pathways in the same cell or that each target is always under the control of A2ARs.
Figure 2. Adenosine A1 and A2A receptors (A1R, A2AR) can form dimers with different metabotropic receptors operated by other neurotransmitters. This
opens the possibility that adenosine may operate hitherto unrecognised entities that may display novel pharmacological properties.
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mainly because most of the studies have focused in the
basal ganglia where A2ARs are by far more abundant
because of their Fabnormal_ large expression in the medium
spiny neurons of the indirect pathway. Thus, the study of
these A2ARs, which have a particular density and subcel-
lular localization in this particular set of neurons, might not
be representative of the more general role of A2ARs in the
most regions of the brain. Outside the basal ganglia, the
function that has mostly been ascribed to A2ARs is
the control of neurotransmitter release, in accordance with
the preponderant presynaptic localization of extra-striatal
A2ARs (see [33]). As previously discussed (see the section
BSubcellular localization of adenosine receptors^), A2ARs
have been shown to facilitate the release of most neuro-
transmitter types (glutamate, GABA, glycine, acetylcho-
line, noradrenaline, serotonin) in different extra-striatal
brain regions. Although it is also known that extra-striatal
A2ARs are also located in the post-synaptic density (although
with a density lower than in nerve terminals), only one report
has so far described the ability of A2AR activation to depolarise
hippocampal neurons by a mechanism that remains to be
unravelled [64].
In conclusion, in relation to the two main adenosine
receptors in the brain, both seem to cause opposite effects
on the release of excitatory neurotransmitters in the brain.
In particular, in glutamatergic nerve terminals, it has been
shown that A1 and A2A receptors are co-located in a subset
of these terminals in the hippocampus [65] and there is a
functional interaction between these two adenosine recep-
tors with opposite effects on glutamate release [32, 66].
Furthermore, extra-striatal A2ARs can also facilitate the
release of some neurotransmitters that are not controlled
by A1Rs, like GABA or noradrenaline. Apart from these
presynaptic effects, A1Rs can also concur to inhibit
neuronal activity by acting post-synaptically, both in distal
dendrites (mainly at the post-synaptic density) as well as in
proximal dendrites.
Whereas most available work provides a strong support
for the effects of A2ARs in controlling neurotransmitter
release and of A1Rs to control both neurotransmitter release
and neuronal excitability, it is important to also consider
other more subtle or indirect mechanisms by which
adenosine receptors might control neuronal function. One
of the subtle effects of adenosine might be to fine-tune other
systems controlling neurotransmitter release [67]. The work
of Correia-de-Sa´ was instructive to understand the key role
of A2ARs in resetting the modulatory systems able to come
into play at the neuromuscular junction. Thus, the increased
activation of A2ARs with increasing frequencies of nerve
stimulation, can shut down the presynaptic nicotinic auto-
facilitatory system [68], reset the muscarinic acetylcholine
receptors [69] and allow the peptidergic presynaptic modu-
latory systems to come into play [70, 71]. Further work by
Sebastia˜o has extended this idea to the brain, where the
peptidergic modulation of excitatory synaptic transmission
in the hippocampus by G protein coupled receptors (oper-
ated by CGRP and VIP) is strictly dependent on the acti-
vation of A2ARs [72, 73]. More recent work has also found
that the effects of BDNF on hippocampal synaptic trans-
mission are also abolished by blocking adenosine receptors
[74] and A2ARs are able to trans-activate TrkB receptors
[75]. This places A2ARs in a key position to shut on and off
the important effects of neurotrophins in the brain. Figure 2
summarises the known modulatory systems whose efficien-
cy is controlled by A2ARs and shows that receptors from all
classes (metabotropic, ionotropic and catalytic) are under
control by A2ARs. These results also prompt the need to
always evaluate the status of adenosine receptors when
studying any other presynaptic modulatory systems, since
the functioning of most of the presynaptic neuromodulatory
systems are in fact under a tight control by adenosine
receptors (see [76]).
It should also be kept in mind that the effects of
adenosine receptor activation are most likely not restricted
to the direct control of neuronal activity. In fact, adenosine
receptors are also located in other cell types in the brain
(astrocytes, microglia, oligodendrocytes) that can indirectly
influence neuronal activity. Figure 3 illustrates the local-
ization of A1Rs and A2ARs in different cell types and com-
partments in the brain, showing that adenosine is indeed
well positioned to participate in neuronYglia communica-
tion. Astrocytes are equipped with all four types of adeno-
sine receptors [77Y82] that control astroglyosis [83Y84]
and the release of different substances that can impact on
neuronal activity [39, 85Y88]. As occurs for the presynaptic
control of neurotransmitter release, adenosine receptors in
astrocytes also fine-tune the action of several other re-
ceptor systems in astrocytes, like metabotropic glutamate
receptors [89, 90], histamine [91], a1-adrenergic receptors
[92] and ATP P2Y receptors [93, 94]. One particular
exciting action of adenosine receptor activation in glial
cells is the control of the expression and release of cyto-
kines [85, 95, 96]. Furthermore, adenosine receptors also
control microglia reactivity [18, 97Y99]. This prompts
the hypothesis, initially raised by Schubert [100] that
adenosine might play an important role in the control of
neuro-inflammation, an issue that will be discussed latter in
more detail in the realm of the neuroprotective role of
adenosine.
Finally, the last topic that should be considered when
discussing the actions of adenosine in the brain is the
ability of adenosine receptors to control metabolism. In fact,
the activation of adenosine receptors can modify the primary
metabolism of most cell types (see [1]) and this is also true
for both neurons and astrocytes [101, 102] and in particular
for the control of glygogen metabolism [51, 103, 104].
However, it still remains to be explored if this modulation
of brain metabolism by adenosine receptors is implicated
in the neuromodulatory or neuroprotective properties of
adenosine or if it might be related with the trophic effects
of purines (see [105]).
Generation of extracellular adenosine
The general presentation of the different roles operated by
adenosine in the brain clearly illustrates that adenosine
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causes different and most often opposite actions by acti-
vating different receptors. Furthermore, it is now becoming
clear that adenosine receptors causing opposite effects can
be co-localised, at least in nerve terminals. Thus, it
becomes of uppermost importance to understand how the
differential activation of the different adenosine receptors
can be effectively controlled to meet the needs of the sys-
tem. One possibility would be that the different adenosine
receptors might have different affinities for their endoge-
nous ligand, i.e. adenosine. However, because it is not pos-
sible to completely eliminate endogenous adenosine (which
is present in all biological preparations) one can only
estimate rough affinities of the different adenosine recep-
tors for adenosine. And most results suggest that the affinity
of adenosine for A1Rs and A2ARs is similar, in the low
nanomolar range. Thus, one has to assume that there might
be different ways of generating adenosine to activate either
A1Rs or A2ARs (reviewed in [1]). The correlate of this
assumption is that one cannot define an Bextracellular
concentration of adenosine,^ but one should instead discuss
an Bextracellular gradient of adenosine.^
The data obtained in hippocampal nerve terminals
provides probably one of the few clear pictures of the
extracellular metabolism of adenosine (which is particu-
larly relevant given that the predominant role of adenosine
is a presynaptic control of neurotransmitter release). Two
main mechanisms have been identified in nerve terminals
for the generation of extracellular adenosine: one is based
on the release of adenosine as such through bi-directional
non-concentrative (or equilibrative) nucleoside transporters
[106]. In fact, inhibition of equilibrative nucleoside trans-
porters can actually decrease the extracellular levels of
adenosine in nerve terminals [107, 108], in accordance
with a build-up of extracellular adenosine involving its
release through equilibrative nucleoside transporters in this
particular compartment of the brain. The second mecha-
nism for the extracellular build-up of adenosine is its for-
mation from released ATP, after its extracellular catabo-
lism by ecto-nucleotidases (reviewed in [109]). Thus, ATP
is stored in synaptic vesicles and nerve terminals release
ATP on stimulation (reviewed in [110]). This release of
ATP is larger the higher the frequency of nerve stimulation
[111, 112] and the contribution of ATP-derived adenosine
increases with increasing frequencies of nerve stimulation
[112, 113]. In contrast, the contribution of adenosine
released as such through equilibrative nucleoside trans-
porters predominates at lower frequencies of nerve stimu-
lation ([112]; see also [114]). Thus, in these hippocampal
excitatory nerve terminals, there are two mechanisms re-
sponsible for the formation of extracellular adenosine and
two adenosine receptors (A1Rs and A2ARs) with opposite
effects on glutamate release. And electrophysiological
studies at these synapses revealed that the inhibitory ef-
fects of A1Rs clearly predominate at low frequencies of
nerve stimulation, since blockade of A2ARs, but not A1Rs,
is devoid of effects [31, 115]. However, stimulation with
burst of high frequencies reveals a tonic activation of
A2ARs [116] and inhibition of ecto-5
0-nucleotidase blunts
the tonic activation of A2ARs [113, 117].
In conclusion, in this particular compartment of the
brain, the available data provide a rationale to understand
the differential activation of A1Rs and A2ARs as a function
of the intensity of functioning of the nerve terminals
(reviewed in [1, 109]), which is based on the different
relative contributions of two possible pathways for the
build-up of extracellular adenosine, as summarised in
Figure 4. This general mechanism of controlling A1R versus
A2AR activation according to the levels of released ATP
seems to be valid for hippocampal excitatory nerve
terminals (reviewed in [1, 109]) and phrenic nerve endings
[113]. However, it is important to stress that different types
of nerve terminals are likely to have different organizations
of extracellular adenosine metabolism and adenosine
receptors as found, for instance, in cortical or hippocampal
cholinergic nerve terminals (reviewed in [109]). One key
aspect of the mechanistic explanation coupling the extra-
cellular metabolism of released ATP with the preferential
activation of A2ARs is the proximal localization of ecto-5
0-
nucleotidase (responsible for the formation of ATP-derived
adenosine) and A2ARs. This has, so far, not been directly
demonstrated to occur in hippocampal nerve terminals.
However, it is striking to note that several physiological
[117, 118] and pathological situations [119, 120] cause a
parallel increase of the activity of ecto-50-nucleotidase and
of the density of A2ARs, in contrast to A1Rs. Furthermore,
in different models, it has been shown that noxious stimuli
cause a parallel increase of the expression of ecto-50-
nucleotidase and of A2ARs [121Y123], strongly supporting
the view that these two molecules are tightly inter-
connected.
In more integrated brain preparations, the relation
between A1R and A2AR activation is less well defined.
Here, it is unlikely that it might be the extracellular
metabolism of adenosine that governs the relative activa-
tion of A1Rs and A2ARs, because there is scarce evidence
to support the co-localization of these two receptors
outside excitatory nerve terminals. Furthermore, the source
of extracellular adenosine is less well defined in more
integrated brain preparations. Thus, most cell types and
compartments in the brain are equipped with equilibrative
nucleoside transporters. However, in integrated brain
preparations, the inhibition or blockade of equilibrative
nucleoside transporters causes an increase rather than a
decrease of extracellular adenosine (reviewed in [124]).
This means than the role of nucleoside transporters is to
clear-up adenosine rather than to promote its release. It is
now well accepted that all cell types release ATP, namely,
neurons, astrocytes or microglia cells, by mechanisms that
remain controversial [125]. Likewise, all cell types are
endowed with ecto-nucleotidases, forming an efficient
enzymatic pathway to convert ATP into adenosine
(reviewed in [126]). However, in most integrated brain
preparations (and in contrast to nerve terminals), the
prototypical inhibitor of ecto-50-nucleotidase, a,b-methyl-
ene ADP, fails to modify the extracellular levels of
adenosine (reviewed in [124]). It is possible that in more
integrated preparations, the conversion of adenine nucleo-
tides into adenosine cannot be effectively prevented. In
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fact, a,b-methylene ADP is a competitive inhibitor of ecto-
50-nucleotidase, but does not affect other ecto-enzymes
able to metabolise AMP (reviewed in [126]). It should also
be kept in mind that the ecto-nucleotidase system is a
notable efficient system, probably organised in a chan-
nelled manner [127] and able to generate adenosine to act
on its receptors in a few milliseconds [128], a time course
faster than the Kcat of soluble enzymes. Thus, in more
integrated preparations, either the concentration of a,b-
methylene ADP fails to equilibrate with ecto-50-nucleotid-
ase or enzymes other than ecto-50-nucleotidase are mostly
responsible for the formation of extracellular adenosine or
there are other (still unknown) pathways of extracellular
adenosine formation that are still to be identified. Note that
in purified nerve terminals, which only account for 1%Y2%
of the volume of more integrated preparations [129],
spatial restrains are decreased and it is the only preparation
where it has been demonstrated that ecto-50-nucleotidase
was the predominant enzymatic activity responsible for the
formation of extracellular adenosine from adenine nucleo-
tides [130]. Thus, in nerve terminals, a,b-methylene ADP
is able to decrease the formation of extracellular adenosine
[107, 108, 112, 117, 118].
In conclusion, in more integrated brain preparations, it
appears that the role of equilibrative nucleoside transporters
is to clear-up adenosine. Hence, the formation of extracel-
lular adenosine should result from the extracellular metab-
Figure 4. Schematic representation of the ability of the extracellular
metabolism of adenosine (and ATP) to determine which adenosine
receptor-mediated effect will be preponderant in glutamatergic nerve
terminals of the rat hippocampus. Thus, at lower frequencies of nerve
stimulation, there is a lower release of ATP, which will form low amounts
of adenosine allowing the nucleoside transporters to contribute for the
accumulation of extracellular adenosine, favouring the activation of A1
receptors. At higher frequencies of stimulation, the release of ATP is
disproportional larger, the extracellular levels of adenosine will be
essentially derived from ATP (after its catabolism by ecto-nucleotidases),
leading to a preferential activation of A2A receptors that are in close
proximity of ecto-50-nucleotidase. ADO, adenosine; AK, adenosine
kinase; NT, neurotransmitter (in this case, glutamate); NTDPase, ecto-
nucleotidases able to convert ATP and/or ADP into AMP; 50-N, ecto-50-
nucleotidase; T, equilibrative nucleoside transporters.
b
Figure 3. All cell types and sub-cellular compartments in the brain are
endowed with different relative proportions (indicated by the relative size
of the circles) of adenosine A1 and A2A receptors (A1R, A2AR) that fulfil
different roles according to their localization. Since all the represented
compartments can also release both ATP and adenosine and are endowed
with ecto-nucleotidases to convert extracellular ATP into adenosine, this
nucleoside is ideally positioned to mediate all conceivable forms of
neuronYglia communication. This scheme also illustrates that the effects
of adenosine in the brain might always result from a balanced modulation
of all cell types and compartments in the brain. COX, cyclooxygenase;
GTL, glutamate transporter; Glu, glutamate; NGF, nerve growth factor;
VSCCs, voltage-sensitive calcium channels.
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olism of released adenine nucleotides, but direct evidence for
this is lacking. Extracellular ATP is the strongest candidate
to act as a primary source of adenosine since it is released in a
controlled manner from neurons (reviewed in [110]) and
from astrocytes [131Y141] as well as from activated
microglia [142]. It has also been proposed that cAMP
could be released from neurons [143], but its contribution
is at best limited [144]. Clearly further work is required to
elucidate the pathways of generation of extracellular
adenosine in the brain, which is a pre-requisite to under-
stand the dynamics of activation of adenosine receptors in
different physio-pathological conditions.
Modification of adenosine metabolism
on stressful conditions
When considering the relevance of adenosine in the realm
of neuroprotection, it is most important to first consider the
consequences of noxious stimuli on the extracellular
metabolism of adenosine. This will allow gaining insight
on the neuroprotective role of endogenous adenosine and
it is also instructive to understand if it makes sense to
pharmacologically manipulate the effects mediated by
adenosine receptors when their tonic activation might be
dramatically modified.
The energy charge is one of the fundamental parameters
(together with the redox status) to define the status of the
primary metabolism of cells. Hence, it is one of the earliest
parameter to be re-adjusted by any stressful stimuli in all
cell types. Based on the tight relation between the levels of
adenosine and the energy charge, it is expectable that the
tissue levels of adenosine will be modified by noxious
stimuli. In fact, the intracellular concentration of ATP is in
the range of 3Y10 mM, i.e. about 100,000 times greater
than that of adenosine (between 10 and 50 nM). Thus,
slight changes in the concentration of ATP will cause
several-fold changes in the intracellular concentration of
adenosine (discussed in [1]). Therefore, it is not surprising
that stimuli ranging from increased neuronal firing to
hypoxia, ischemia or cell poisoning will cause increases in
the extracellular levels of adenosine (reviewed in [124];
[1]). However, the mechanism responsible for coupling the
expected increase in the intracellular levels of adenosine
and the observed increased levels of extracellular adeno-
sine is still not clear.
The simplest explanation would be that the adenosine
formed intracellularly would be released through equilib-
rative nucleoside transporters thus leading to increased
levels of extracellular adenosine. According to this sce-
nario, there is a good correlation between the graded in-
tensity of the noxious stimuli applied, the drop in energy
charge of the studied brain tissue and the extracellular
levels of adenosine (e.g., [145, 146]). Also, blockade of the
intracellular enzymatic pathways responsible for the con-
sumption of intracellular adenosine (mainly adenosine
deaminase and adenosine kinase) increase the extracellular
levels of adenosine under different noxious conditions in
brain preparations (e.g., [147, 148]; reviewed in [124]).
However, the inhibition of equilibrative nucleoside trans-
porters increases the extracellular levels of adenosine. This
tells us that the role of equilibrative nucleoside transporters
is mostly to take up rather than to release adenosine, as
occurs during non-stressful conditions (reviewed in [1];
[124]). The obvious alternative is that the formation of
extracellular adenosine should result from the extracellular
catabolism of released adenine nucleotides triggered by
noxious stimuli. Some few studies have reported a release
of ATP as such during stressful stimulation of brain prep-
arations [149Y153]. Also, both axonal depolarization and
increased glutamate levels, both of which are hallmarks of
potential neurotoxic conditions, are effective triggers of
ATP release [154Y156]. And, although it remains to be
tested if this stress-induced ATP release contributes for the
extracellular build-up of adenosine, it is interesting to note
that there is an up-regulation of ecto-nucleotidases upon
noxious brain conditions [120, 157Y159].
This presentation and discussion of the data available on
purine release during noxious brain conditions clearly tells
us how little is known about the pathways of generation of
extracellular adenosine in stressful conditions. In fact,
neither the pathways leading to the build-up of extracellu-
lar adenosine nor the major cell type (or sub-cellular
compartments) contributing for this elevation of the
extracellular levels of adenosine caused by noxious stimuli
have been experimentally tackled.
In spite of our ignorance on how extracellular adeno-
sine is formed, it is never the less evident that noxious
stimuli trigger a robust increase in the extracellular levels
of adenosine that reaches micromolar concentrations in
the extracellular fluid of stressed brain preparations
(reviewed in [124]). Given that the affinity for adenosine
of the most abundant adenosine receptors (A1Rs and
A2ARs) is in the low nanomolar range, the obvious
question that pops up is whether these increased levels of
endogenous adenosine are enough to saturate A1Rs and
A2ARs. In fact, if this was to occur, it would make little
sense to devise any therapeutic neuroprotective strategy
based on the use of agonists of adenosine receptors. This
does not appear to be the case since inhibition of the key
enzymatic activities thought to control the availability of
adenosine still potentiates the neuroprotective effects of
endogenous adenosine. In fact, inhibition of adenosine
kinase is strongly neuroprotective in different animal
model of brain injury [160Y166], and some, but not all
studies (see [167, 168]), also found that inhibitors of
adenosine deaminase were neuroprotective [169, 170]. This
clearly indicates that it is justified to invest a greater effort
into understanding the changes of the metabolism of
adenosine caused by noxious stimulation.
Acute A1 receptor activation increases the threshold
for acute neurodegeneration
When considering which adenosine receptor plays a major
role in affording neuroprotection in the brain, the strongest
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candidate is obviously the A1R. This is because A1Rs have
a major inhibitory effect on synaptic transmission and
neuronal excitability (see BModulatory roles of adenosine^)
and also because they are, by far, the most abundant
adenosine receptor subtype in the brain. And, in fact, a
diversity of studies in different brain preparations of different
species using different noxious stimuli, consistently found
that the acute activation of inhibitory A1Rs is neuroprotec-
tive (elegantly reviewed in [171]). Thus, in isolated neurons
and in brain slices, A1R activation reduces damage to
neurons, whereas A1R antagonists potentiate damage
(reviewed in [171Y174]). Likewise, in whole animals subject
to ischemia or other type of brain noxious stimuli (e.g.,
epileptic models, trauma, exposure to excitotoxins), it is also
concluded that the acute activation of A1Rs is neuro-
protective, whereas A1R antagonists potentiate damage
(reviewed in [171Y176]).
In conclusion, the data available are notably consistent
in establishing a neuroprotective role for A1R acute
activation in noxious brain conditions in adult animals.
Likewise, the worsening effect caused by A1R antagonists,
as well as the beneficial effect caused by enhancing the
extracellular levels of adenosine (reviewed in [171Y174])
or using allosteric enhancers of A1Rs [177], also indicates
that the tonic activation of A1Rs is an endogenous neuro-
protective system in stressful brain situations.
However, the therapeutic interest of A1R agonists has
several limitations that hamper its usefulness as novel
neuroprotective drugs. The first major drawback is due to
the profound cardiovascular effects of A1R agonists (e.g.,
[178, 179]), which are most worrying because A1R ago-
nists have a poor brain permeability [180, 181]. The second
limitation is related to the short Fwindow of opportunity_ of
A1R agonists, which is limited to a few hours, at most,
after the initiation of the brain insult (reviewed in [171,
173, 174]; but see [182]). This is aggravated by the fact that
is not conceivable to administer A1R agonists chronically (as
a preventive strategy) because it causes an effect inversion,
i.e. chronic A1R stimulation actually exacerbates neuronal
loss caused by noxious brain stimulation (reviewed in
[183]). Finally, the last major limitation to develop A1R
agonists as neuroprotective drugs is the observation that the
effect of A1R activation desensitize in chronic stressful
brain conditions, as shall be discussed in more detail in
BLong-term desensitization of A1 receptors and up-regula-
tion of A2A receptors by chronic noxious conditions.^
In conclusion, it appears that the activation of A1Rs is
an endogenous neuroprotective system, but its usefulness
is limited to acute noxious brain conditions, i.e., to control
the onset or enhance the threshold of neuronal damage.
Long-term desensitization of A1 receptors and
up-regulation of A2A receptors by chronic
noxious conditions
Adenosine A1Rs belong to the G protein-coupled receptor
family but, unlike most in their family, A1Rs have a long
half-life (e.g., [184]) and seem to be resilient to desensi-
tization [185]. In fact, several works suggest that neuronal
A1R desensitization occurs in large time frames (12Y24 h)
of exposure to exogenously added A1R agonists in vitro
(e.g., [184, 186, 187]) as well as in vivo (e.g., [188, 189]).
The time course of desensitization of A1Rs is particularly
critical to understand if adenosine maintains its neuro-
protective efficiency in chronic noxious brain situations.
In animal models of epilepsy as well as in patients with
temporal lobe epilepsy, i.e., in situations causing a long-
lasting enhanced release of adenosine (e.g., [190Y192]),
there is a long-term decrease in the density of A1Rs in
different brain regions [120, 193Y195], which is also
observed in patients with mesial sclerosis ([196]; but see
[197]). This decreased density of A1Rs is in general
agreement with the development of tolerance in relation
to the anti-convulsive effects of A1 receptor agonists
[198, 199] that is accompanied by a reduced potency of
A1R agonists [120]. In other chronic neurodegenerative
conditions, such as Alzheimer’s disease, the density of
A1Rs is also reduced ([206, 397, 398]; but see [207]).
Likewise, several studies showed that short periods of
brain ischemia, which also trigger a robust increase in the
extracellular levels of adenosine ([121]; reviewed in
[172]), produce a long-lasting decrease in the density of
A1Rs in several brain regions (e.g., [200Y202]). Again, this
hypoxia-induced homologous desensitization of A1Rs
[203] is accompanied by a loss of efficiency of A1R agonists
when applied more than one hour after the hypoxia period
(reviewed in [171, 173, 174]; but see [182]). This homo-
logous desensitization of A1Rs has also been documented
in other situations which trigger the release of adenosine.
Thus, the implementation of long-term potentiation, which
triggers a robust release of adenosine (see [112]), also
decreases the efficiency of A1R modulation of synaptic
transmission [204, 205].
In conclusion, several physio-pathological conditions
able to generate endogenous extracellular adenosine, cause
a long-term down-regulation of A1Rs that contributes to
hamper the neuroprotective effectiveness of the A1R sys-
tem in chronic noxious brain conditions. This is in agree-
ment with the idea that the activation of A1Rs is important
to control the acute onset of neuronal dysfunction and/or
neurodegeneration, but that these A1Rs suffer a long-term
desensitization making the A1R system less appealing
as a target for the development of neuroprotective agents
aimed at interfering with long-term chronic noxious brain
conditions.
Considerably fewer studies have been performed to
investigate the long-term effect of noxious stimuli to the
density and efficiency of A2ARs in the brain. Most studies
have focused on the striatum, where both the density and
the role of A2ARs are biased by their particular localization
with high density in a particular subset of neurons, the
medium spiny neurons of the indirect pathway. Interest-
ingly, in clear contrast with what occurs for A1Rs, chronic
stressful stimuli directed to the basal ganglia cause an
increased expression and density of A2ARs, as observed in
animal models of Parkinson’s disease (e.g., [208, 209]) and
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in Parkinsonian patients ([210]; see also [211, 212]). It is
also possible that the expression of A2ARs might also
increase in animal models and patients with Huntington’s
disease, since the expression of A2ARs is increased in
neurons over-expressing huntingtin [213]. However, the
major loss of medium spiny neurons in this condition may
mask the increased density of A2ARs in the remaining viable
neurons [211, 214, 215]. Interestingly, this idea that brain
A2ARs might be up-regulated by noxious stimuli was most
evident in a recent study focusing on extra-striatal regions.
It was observed that convulsive behaviour caused a long-
term robust enhancement of the density of cortical A2ARs,
which contrasted with the decreased density of cortical
A1Rs [195]. Likewise, in brain sections from patients with
Alzheimer’s disease, a greater density of A2ARs was also
observed, which was reported to be confined to microglia
processes [207]. This is in agreement with the recently
reported increased in the density of A2ARs in activated
microglia cells [216] and with the ability of cytokines to
up-regulate A2ARs [217]. This increase in A2AR density
and efficiency is also observed in other cell models
systems, like PC12 cells (see [121, 218]) or activated
lymphoid cells [219Y223]. Finally, an up-regulation of
A2ARs was also reported in schizophrenic patients [224].
In conclusion, the balance between A1Rs and A2ARs in
the brain appears to be modified by stressful stimuli. In
fact, stressful stimuli cause a decrease of A1R density and
efficiency whereas there is an increased expression and
density of A2ARs. This confirms the idea that the neuro-
protective effect of A1Rs is probably most relevant at the
onset of brain damage, whereas A2ARs might come into
play at latter stages of brain damage and in particular in
chronic noxious brain conditions that are characteristic of
neurodegenerative diseases.
A2A receptor blockade confers robust neuroprotection
The presentation of the available evidence to suggest an
up-regulation of A2ARs by noxious stimuli makes it logical
to conceive that the manipulation of the activity of this
receptor might affect the outcome of brain damage. But the
first report by Phillis’ group that a non-selective A2AR
antagonist (CGS 15943) attenuated cerebral ischemic
injury [225], in contrast to A1R antagonists [226], appeared
as a serendipitous observation. Similar observations were
made by von Lubitz in a similar gerbil model of brain
ischemia [227]. However, this concept of A2AR blockade
as a neuroprotective strategy was difficult to understand at
the time and consequently was not widely accepted until
the group of Ongini and the group of Chen demonstrated
that both the pharmacological blockade of A2ARs with a
selective antagonist (SCH 582610) [228] as well as the
genetic inactivation of A2ARs (using A2AR knockout mice)
[229] conferred a robust neuroprotection in animal models
of focal ischemia.
In the last three years, numerous studies by different
groups using different noxious brain stimuli have system-
atically confirmed this ability of A2AR blockade to confer
robust neuroprotection (reviewed in Table 1). Interestingly,
this neuroprotection afforded by A2AR blockade was more
robust in cortical regions than in the basal ganglia, where
these A2ARs are considerably more abundant [228, 229,
231]. This emphasises again that the Fabnormal_ high
density of A2ARs in striatal medium spiny neurons of the
indirect pathway fulfils a very particular role in the control
of striatal circuitry and that our knowledge about striatal
A2ARs should not be extrapolate to understand the general
role of A2ARs in the brain. Nevertheless, although A2AR
blockade is particularly effective in preventing cortical and
hippocampal damage [225, 229, 231Y237], it is also
effective in attenuating striatal damage following brain is-
chemia [229, 231], exposure to quinolinic acid [230, 238],
3-nitropropionic acid [239, 240], malonate [241] or MPTP
[242, 243].
One particular interesting aspect related with the neuro-
protection derived from the blockade of A2ARs is that the
effects of A2ARs do not seem to desensitize with prolonged
administration of A2AR antagonists [244, 245]. This con-
trasts with the neuroprotection based on the activation of
A1Rs, which desensitises over time (see BLong-term de-
sensitization of A1 receptors and up-regulation of A2A
receptors by chronic noxious conditions^). In particular,
long-term exposure of caffeine leads to a rapid A1R de-
sensitization but maintenance of A2AR-mediated responses
[246]. Thus, the maintenance over long periods of the
central effects of A2AR antagonists, probably related to the
stress-induced up-regulation of A2ARs (see BLong-term
desensitization of A1 receptors and up-regulation of A2A
receptors by chronic noxious conditions^), makes this
receptor an attractive target for prolonged manipulation of
brain injury. The use of A2AR antagonists as novel neuro-
protective drugs is also favoured by their beneficial phar-
macokinetic profile. In fact, the doses of A2AR antagonists
that afford neuroprotection are considerably lower than
these producing peripheral effects, namely cardiovascular
effects (see [247, 248]). In fact, the neuroprotective
properties of A2AR antagonists are lost on increasing their
dosage [237Y240], but it is still unclear if this is related to
an increased contribution of peripheral effects, to a dif-
ferential blockade of different populations of A2ARs or to a
loss of selectivity of the currently available A2AR antago-
nists. Finally, the neuroprotective effective doses of A2AR
antagonists are also devoid of other measurable central
effects, which is in accordance with the lack of evident
secondary effects in the on-going clinical trials with A2AR
antagonists (unpublished results). In conclusion, the lack of
peripheral or other evident central effects together with the
maintenance over time of A2AR-mediated responses make
A2ARs particular interesting targets to develop novel and
effective neuroprotective drugs.
One important aspect that remains to be unravelled is the
mechanism(s) by which A2AR blockade affords such robust
neuroprotection. This is particularly intriguing given that
cortical and hippocampal A2ARs have a low abundance (in
the range of 20 fmol/mg of protein compared to a 50-times
greater density of A1Rs; [7]) and the amplitude of the effect
resulting from A2AR activation is discrete, especially when
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evaluating neuronal activity. Probably because several
groups reported an ability of A2ARs to control the release
of glutamate both in the cerebral cortex [249Y251], hippo-
campus [31, 32, 252] and striatum [26, 230, 253Y257], the
hypothesis that the A2AR-mediated control of glutamate
release might be the explanation for the neuroprotective
effects of A2ARs became popular [238, 258]. Indeed, some
studies reported that A2AR activation was involved in
enhancing the extracellular levels of glutamate triggered by
noxious stimuli [231, 238, 249, 251]. However, in more
simplified models of neuronal dysfunction, it was not
possible to confirm that the presynaptic modulation of
glutamate release by A2ARs was related to their control of
neuronal damage. In fact, when studying hypoxia- or
ischemia-induced depression of synaptic transmission,
where the presynaptic control of glutamate release is related
to the post-hypoxic recovery of synaptic transmission (see
[259]), blockade of A2ARs is essentially devoid of effects
[259, 260]. An interesting alternative to reconcile the
control of extracellular glutamate levels by A2ARs with the
neuroprotective role of A2AR blockade would be a control
by A2ARs of the release and clearance of glutamate by
astrocytes. Thus, A2AR activation can inhibit glutamate
transport into astrocytes [261], in particular GLT-1 [40]
and enhance the release of glutamate from astrocytes [39,
40]. However, strong arguments have been provided to
support the view that the role of glutamate transporters
during stressful stimuli is to contribute for the extracellular
build-up of glutamate rather than for its removal (see, e.g.,
[262]). In conclusion, it remains to be determined what
might be the contribution of the A2AR modulation of
astrocytic glutamate transporters in the realm of the
neuroprotection afforded by A2AR antagonists in noxious
brain conditions.
It is also important to consider that A2AR antagonists are
effective in preventing neurotoxicity in isolated neurons in
culture. In fact, both caffeine and antagonists of A2ARs
(SCH 58261 or ZM 241385) effectively prevent the neuro-
toxicity induced by exposure of cerebellar [263] or hippo-
campal neurons [264] to the fragment 25Y35, 1Y40 or 1Y42
of b-amyloid protein (Ab), a putative causative factor of
Alzheimer’s disease [265]. And there is no evidence to
suggest that Ab enhances glutamate release, since the
effect of Ab is the opposite, i.e. to depress glutamatergic
transmission (reviewed in [266]). Thus, one has to assume
that A2ARs might have direct effects on neurons to control
their susceptibility to neurotoxic stimuli. The possible con-
trol by A2ARs of one the receptor systems most frequently
involved in neurodegeneration, the NMDA receptor, does
not appear to be a likely candidate. In fact, it has been
shown that A2AR activation actually inhibits NMDA
receptors in striatal neurons [267 Y269] and A2AR blockade
increased NMDA-dependent neurotoxicity in the hippo-
campus [270]. Alternatively, A2ARs might control the
apoptotic machinery in neurons and other cell types in
the brain (see [264]), in a manner similar to the control by
A2ARs of apoptosis in PC12 cells [271Y273] or in neu-
trophils [274Y276].
Another hypothesis, first advanced by Schubert to
understand adenosine neuroprotection would be the possi-
Table 1. Neuroprotective effects afforded by A2AR blockade/inactivation in in vivo models of adult brain toxicity.
Experimental model Manipulation Effect Reference
Global ischemia, gerbil CGS 15943 0.1 mg/kg i.p. Protection (HIP cell loss) [225]
Global ischemia, gerbil CSC 0.1 mg/kg i.p. Protection (HIP cell loss) [226]
Forebrain ischemia, gerbil CSC 1 mg/kg i.p. Protection (HIP cell loss) [227]
Forebrain ischemia, rat SCH58261 0.01 mg/kg i.p. Protection (CTX infarct vol.) [228]
Forebrain ischemia, mouse A2AR knockout Protection (CTX, STR infarct vol.) [229]
Forebrain ischemia, rat SCH58261 0.01 mg/kg i.p. Protection (CTX, STR infarct vol.) [231]
Forebrain ischemia, rat SCH58261 0.01 mg/kg i.v. Protection (CTX c-fos density) [233]
Ischemia + hyperglycemia, rat ZM241385 1 mg/kg i.p. Protection (HIP cell loss) [234]
KA intra-HIP, rat ZM241385 2.5 pmol intra-HIP Protection (HIP cell loss) [235]
KA i.c.v., mouse DMPX 20 mg i.c.v. Protection (HIP cell loss) [236]
KA i.p., rat SCH58261 0.01Y0.05 mg/kg i.p. Protection (HIP cell damage) [284]
LPS i.c.v., rat SCH58261 5 pmol, i.c.v. Protection (HIP LTP) [285]
QA + X/XO intra-HIP, rat ZM421385 25 pmol intra-HIP Protection (HIP cell loss) [232]
SCH58261 50 pmol intra-HIP
CSC 100 pmol intra-HIP
QA intra-STR, rat DMPX0.2 mg intra-STR Protection (CTX EEG) [237]
QA intra-STR, rat SCH58261 0.01 mg/kg i.p. Protection (CTX EEG, STR glyosis) [238]
3-NP i.p., rat, mouse A2AR knockout Protection (STR lesion vol.) [239]
MSX-3 5 mg/kg i.p.
3-NP i.p., mouse A2AR knockout Protection (STR lesion vol.) [240]
CSC 5Y20 mg/kg i.p.
Malonate intra-STR, rat, mouse DMPX 5 mg/kg i.p. Protection (STR TH, DA levels) [241]
MPTP i.p., mouse A2AR knockout Protection (STR DAT, DA levels) [242]
MPTP i.p., rat 6-OHDA intra-STR KW6002 1Y10 mg/kg p.o. Protection (STR DAT, DA levels) [243]
CTX, cortical; DA, dopamine; DAT, dopamine transporters; EEG, electroencephalography; i.c.v., intracerebroventricular; i.p., intraperitoneal; i.v.,
intravenous; HIP, hippocampal; KA, kainate; KO, knockout; LPS, lipopolyssacharide; LTP, long-term potentiation; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; 3-NP, 3-nitropropionic acid; p.o., oral administration; QA, quinolinic acid; STR, striatal; TH, tyrosine hydroxylase; vol., volume; X,
xanthine; XO, xanthine oxidase.
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bility that A2ARs might control the process of neuro-
inflammation [277]. The process of neuro-inflammation is
known to contribute for the spreading of neuronal damage
in different noxious brain conditions and particular atten-
tion is currently focused on the therapeutic possibilities of
controlling neuro-inflammation as a strategy to attenuate
the neurological consequences of neurodegenerative dis-
eases (reviewed in [278, 279]). Since the brain is not
subject to the actions of the inflammatory system under
physiological conditions (immune privilege of the brain;
reviewed in [280]), it is generally accepted that the initial
trigger of neuro-inflammation is dependent on the re-
cruitment and activation of microglia cells, which are
brain-resident (reviewed in [281]). Accordingly, activated
microglia are found in most brain noxious conditions such as
ischemia, trauma, brain infections, epilepsy, Parkinson’s,
Alzheimer’s or Huntington’s disease (reviewed in [278];
[279, 282]) and activated microglia are even considered
one of the most sensitive sensors for pathological events in
the brain (see [283]). Some evidences suggest that A2ARs
can control the detrimental neuronal consequences associ-
ated with neuro-inflammation. Blockade of A2ARs com-
pletely prevented the recruitment of activated microglia to
the CA3 region of the hippocampus in rats injected with
kainate [236]. However, this might either be due to a
direct effect of A2ARs known to be present in microglia
cells [41, 42, 216] or because A2AR antagonists control the
evolution of the severity of convulsion and associated
neurotoxicity triggered by cumulative sub-threshold amyg-
dala kindling or by kainate injection [284], which pre-date
microglia recruitment. It was also recently shown that an
A2AR antagonist (SCH 58261) can prevent the hippocam-
pal neuronal dysfunction and neurotoxicity triggered by the
direct administration of lipopolyssaccharide (LPS) [285], a
potent inflammatory trigger and activator of microglia
cells (see e.g., [286, 287]). Interestingly, SCH 58261 also
attenuated the LPS-induced neuro-inflammation, as evalu-
ated by the abolishment of LPS-induced increase in interleu-
kin 1b levels and the recruitment of activated microglia
[285]. This shows that A2AR blockade effectively control
neuro-inflammation and the neuronal dysfunction and
damage resulting from a neuro-inflammatory status in the
brain. However, it does not allow stating that microglial
A2ARs play a key role in controlling the involvement of
A2ARs in neuronal damage. In fact, studies with cultured
cells showed that adenosine can directly attenuate neuronal
damage caused by administration to neurons of medium
from activated microglia cultures [98]. The development of
a neuro-inflammatory process depends not only on micro-
glia activation, but also on the participation of astrocytes
(e.g., [288]) and neurons (e.g., [289]), as well as on the
involvement of infiltrating myeloid cells (see [282, 290,
291]). Interestingly, a recent elegant study by the group of
Jiang-Fan Chen showed that brain resident A2ARs might
only play a minor role in controlling neurodegeneration, at
least in an animal model of focal ischemia [292], which
causes a major disturbance of the bloodYbrain barrier with
the easier invasion of circulating myeloid cells (reviewed
in [293]). By comparing the infarcted area in the cerebral
cortex of +-irradiated wild-type mice receiving a bone
marrow transplant from A2AR knockout mice and +-
irradiated A2AR knockout mice transplanted with bone
marrow from wild-type mice, they found that a superior
neuroprotection was observed in the second group (i.e.,
which possessed A2ARs in myeloid cells but not in the
brain). It remains to be tested if A2AR in myeloid cells also
play a key role in other brain noxious conditions where the
infiltration of these cells into the brain is less well
documented.
This proposal that the effect of A2ARs in myeloid cells is
most important for the role of A2ARs in the control of brain
damage is surprising based on the well established robust
role of adenosine in attenuating (rather than exacerbating)
inflammation in the periphery ([294]; reviewed in [295,
296]). In fact, adenosine is a potent anti-inflammatory agent
with A2ARs triggering BOFF^ signals in activated immune
cells, which constitutes one of the most fundamental and
immediate tissue-protecting mechanisms (reviewed in
[295, 296]). A2AR agonists were even named Bthe most
potent anti-inflammatory drug known to mankind.^ Ac-
cordingly, activation of A2ARs has been shown to confer a
robust protection against tissue damage from ische-
miaYreperfusion injury in different organ such as heart
[297Y299], blood vessels [300], kidney [301, 302], liver
[303, 304], lung [305, 306], joints [307], skin [308, 309],
and even in the spinal cord [310, 311] and in the brain
following hemorrhage [312] or acute infection [313]. Thus,
it is the activation (rather the blockade) of A2ARs that
confers protection against damage triggered by inflamma-
tion in peripheral tissues, precisely the opposite of what is
observed in the damaged adult brain. Moreover, A2AR
blockade actually exacerbates tissue damage involving
inflammatory reactions in the periphery (reviewed in
[295, 296]), instead of the tissue protection, as observed
in noxious brain conditions. Furthermore, all studies
available indicate that the activation of A2ARs inhibits the
release of pro-inflammatory cytokines from inflammatory
cells, such as macrophages (e.g., [223, 314Y316]), dendritic
cells [220, 221], monocytes [317Y319] or T cells [320,
321]. This latter cell type, in particular CD4+ T cells, are
most relevant since it was recently shown that the key role
of A2ARs in attenuating peripheral tissue damage from
ischemiaYreperfusion injury is due to the activation of
A2ARs in CD4
+ T cells [322]. Since the depletion of
CD4+YCD25+ regulatory T cells has been shown to promote
survival of neurons after brain insults [323], in a manner
regulated by metabotropic receptors such as dopamine D1
receptors [324], it would be interesting to test if A2ARs
might affect this particular population of T cells to control
brain injury. However, the urgent need remains to provide a
logical explanation for the fundamentally opposite effects of
A2ARs in cell death involving inflammatory reactions in the
brain and in the periphery.
In conclusion, there are currently five concurring
hypothesis to explain the robust neuroprotective effects
afforded by A2A receptors in noxious brain conditions in
adult animals: (1) presynaptic control of glutamate release;
(2) control of astroglyosis and of glutamate uptake and re-
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lease by astrocytes; (3) direct control of neuronal viability
by interference with pathways of cell death; (4) control of
microglia reactivity; (5) control of the reactivity of infil-
trating lymphoid cells. As discussed, all these hypotheses
have pitfalls that limit their acceptance. Most likely, it may
be that different conjunctions of these mechanisms might
come into play according to the type of insult, since dif-
ferent insults are likely to operate different demises of
neuronal damage.
Therapeutic neuroprotective potential based on
adenosine in the adult brain
The results discussed so far allow to draw a general picture
of the role of adenosine in the control of brain damage
involving A1 and A2A receptors: activation of A1Rs would
have an important role to control the early onset of brain
damage, whereas blockade of A2ARs would have a pre-
ponderant effect in the latter stages of brain damage. And
since the efficiency of A1Rs decreases upon chronic nox-
ious stimuli (see BAcute A1 receptor activation increases
the threshold for acute neurodegeneration^), whereas the
efficiency of A2AR antagonists seems to be preserved
(probably due to the down-regulation of A1Rs and up-
regulation of A2ARs by noxious stimuli), the use of A2AR
antagonists currently seems to be the most promising brain
neuroprotective strategy based on the adenosine neuro-
modulatory system in adult animals [325]. Accordingly,
A2AR antagonists are being developed as novel anti-
parkinsonian drugs [326Y328], which are currently under
clinical trials with promising results (e.g., [329]).
However, it might still be possible to further refine the
efficiency of a neuroprotective strategy based on adenosine
neuromodulation. In fact, although there is a general down-
regulation of A1Rs caused by noxious stimuli, this does not
mean that the ability of A1Rs to control neuronal damage is
eliminated. In fact, some reports indicate that A1R-
mediated neuroprotective effects may still be achieved in
chronic brain noxious conditions in adult animals, such as
in animal models of epilepsy [165, 330, 331], multiple
sclerosis [332], paroxysmal dystonia [333] or 3-nitropionic
acid-induced neurotoxicity [334]. It has already been
discussed that the use of A1R agonists as neuroprotective
tools in vivo may be of limited use because of their
profound peripheral effects (see BAcute A1 receptor activa-
tion increases the threshold for acute neurodegeneration^).
However, it might be possible to explore the potential of
inhibitors of the main enzymatic pathway controlling the
consumption of adenosine in the brain, i.e. adenosine
kinase. Some concerns were initially raised with respect to
the efficiency of this approach, because it was reported
that ischemia might cause a down-regulation of this
enzymatic activity in cultured cells [122, 335, 368].
However, a recent careful study carried out in vivo
established the maintenance of the activity of adenosine
kinase after convulsions and most importantly, showed that
the inhibition of adenosine kinase was effective over long
periods of time (up to 1 month in rodents), without
observable peripheral side effects [165]. Thus, it is now
proposed that the simultaneous enhancement of the
extracellular levels of adenosine by inhibition of adenosine
kinase (to burst A1R activation) together with antagonists
of A2ARs might be the most efficient neuroprotective
strategy based on adenosine neuromodulation to prevent
brain damage in adult animals. It is hoped that this
hypothesis might be confirmed in animal models of disease
in the future.
The consequences of adenosine neuroprotection differ
in the newborns
Whereas it is now possible to draw a consistent picture about
the roles of A1 and A2A receptors in controlling neuronal
damage in adult animals, the same is not true in the case of
fetus or newborns animals. Brain A1Rs and A2ARs are
ontogenically regulated and, although A1 and A2A recep-
tors are already present at early developmental timepoints,
their expression and density undergo a striking burst at
birth and major increases until P9YP15 [336Y340]. Some
groups [338, 341] suggested that the efficiency of A1Rs
might be reduced in the immature brain. However, several
central A1R-mediated effects, like the control of epilepto-
genesis [342Y344], of axonal growth [345, 346], of brain
metabolism [347] and of synaptic transmission [348] have
been documented to occur in pups or newborn animals,
suggesting that A1Rs are functional (reviewed in [349]).
However, A1R agonists seem to be essentially ineffective
in protecting against ischemia-induced damage in the
immature brain [341, 350]. The activation of A1Rs might
even be detrimental for the immature brain, since A1R
activation inhibits neurite outgrowth [351, 352], which
may be the reason for the ability of caffeine and A1R
antagonists to prevent the prevalent condition of periven-
tricular leukomalacia in newborns [346]. Interestingly, the
acute increase of extracellular adenosine affords neuro-
protection against ischemic insults in the immature brain
[353]. This may make sense if one considers that the role of
A2ARs in controlling neuronal damage is also the opposite
in the immature brain and in adult animals. In fact, whereas
A2AR blockade is a consistent neuroprotective strategy
against brain damage in adult animals, brain damage is
aggravated in immature A2AR knockout mice [354].
In conclusion, it appears that the roles of adenosine in the
control of brain damage are fundamentally the opposite in
fetus/newborns and in adult animals. Thus, whereas A1R
activation affords neuroprotection in the adult animals, its
role in the immature brain might be predominantly
deleterious [346]. In contrast, whereas blockade of A2ARs
confers brain neuroprotection in adult animals, it aggra-
vates damage in the immature brain. This opposite impact
of adenosine receptor activation on neuronal viability
might not necessarily be due to a different functioning of
A1Rs and A2ARs in immature and mature neurons, but
instead to an opposite effect of intracellular calcium levels
in immature and mature neurons. In fact, whereas the
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activation of NMDA receptors and the rise in intracellular
free calcium concentrations are two well defined hallmarks
of neurotoxicity in neurons from adult animals (e.g., [355]),
these features appear to be fundamental for the survival of
immature neurons [356]. In fact, A1R activation in cultured
cortical neurons (from newborn rats) decreases NMDA
receptor function and voltage activated calcium channels in
a manner analogous to that found in adult rats [356Y358]
but this lead to a decreased neuronal viability [356] rather
than a neuroprotection, as observed in adult brain prepa-
rations. Thus, it appears that neuronal adenosine receptors
maintain their way of functioning in newborn neurons, but
it is the mechanism of neuronal death that is fundamentally
the opposite in mature and in immature neurons.
These modifications of the effects mediated by adeno-
sine and eventually of the coupling of adenosine receptors
should be kept in mind when considering the use of cultured
brain cells as experimental models to study purinergic
modulation, since these preparations are obtained from
embryos or newborns. Some studies in cultured brain
preparations found that A1R activation or A2AR blockade
were neuroprotective [263, 264, 359Y361], whereas other
found patterns of control of neuronal death by manipu-
lation of A1Rs [362Y364] or A2ARs [365, 366] different
from these observed in adult animals. Furthermore, there is
evidence to suggest that the metabolism of adenosine in
preparations from newborn animals [348] or in neuronal cell
cultures [367, 368] also differs from adenosine metabolism
in brain preparations of adult animals.
Adenosine neuroprotection and neurodegenerative
diseases on aging
The word of caution on the possible limitations of the
extrapolation of the usefulness of the adenosine system for
neuroprotection, from adult animals to the immature
brain, obviously raises the question of the applicability
of the proposed strategies of adenosine neuroprotection in
the elderly. This is particularly relevant since most of the
proposed therapeutic applications based on the manipulation
of the adenosine system (Parkinson’s and Alzheimer’s
disease, brain ischemic conditions, epilepsy, sleep dis-
orders) are prevalent in the elderly, but the experimental
work is largely carried out in young adult animals. Thus, one
issue that needs to be established before translation of
animal work into disease in humans is whether there are
changes in the adenosine neuromodulatory system on aging,
as it was found to occur for the immature brain.
In aged animals, it is observed that there is a decreased
expression [369] and density of A1Rs in cortical and
hippocampal regions ([370Y375]; but see [376]), whereas
the density of A2ARs increases [31, 372, 377]. This is
paralleled by a decreased efficiency of A1R agonists
[375, 378Y380] and by an increased G protein coupling
[377] and efficiency of A2ARs in limbic regions [31, 377].
Interestingly, the modification of the status of A2ARs in aged
animals is different in the basal ganglia from that in
cortical regions. In fact, there is a decreased expression
[381] and density of A2AR in the striatum of aged rats
[376, 382Y384]. However, since the role of A2ARs in
motor control is tightly linked to dopaminergic signalling
(reviewed in [6, 28]) and there is also a reduction in the
density of dopamine D2 receptors in the striatum of aged
rats even greater than that of A2ARs [382, 383], the
motor effects of A2AR antagonists are increased in aged
animals [385]. This again stresses the differences between
striatal and extra-striatal A2AR and the limitations in
extrapolating any information from striatal A2ARs to our
understanding of the role of extra-striatal A2ARs. It is
interesting to note that the changes in aged animals of the
relative density of A1Rs versus A2ARs in cortical regions
is similar to that found upon noxious brain conditions
(i.e., down-regulation of A1Rs and up-regulation of
A2ARs). This opens the question of whether the change
of status of A1/A2A receptors in aged animals results from
aging viewed as a physiological stress condition or
whether the modification of the adenosine receptor
system evolves to compensate the general loss of
efficiency of functioning of brain circuits [386, 387].
Future aging studies (rather than comparisons between
groups of adult and aged animals) will be required to
elucidate these issues. This might be particularly relevant
in view of the observation that A1Rs seem to control the
life-span of mice, since the life expectancy of A1R
knockout mice is significantly lower than that of their
wild-type littermates [388].
In aged animals, there is not only a modification in the
densities of A1Rs and A2ARs in the brain, but there is also
a modification of the extracellular metabolism of adeno-
sine (see data and references in [118]). The most surprising
observation is that there is a major decrease in the tonic
A1R activation in hippocampal preparations from aged rats
([380]; in agreement with the results in [375, 379, 389]; but
see [390Y392]). This might eventually contribute for the
greater susceptibility of brain tissue from aged animals to
stressful stimuli, since the main role of A1Rs appears to be
the control of the threshold of onset of neuronal damage.
However, these studies comparing the extracellular
metabolism and A1 versus A2A receptor-mediated effects
between young adult and aged animals allow anticipating
that the currently proposed best adenosine-based strategy
for neuroprotection seems particularly adequate for aged
animals. In fact, in aged animals there is a decrease in the
extracellular levels of adenosine acting on A1Rs and there
are increased levels of A2ARs that are more efficient that in
the brain from young adult animals. Thus the combination
of adenosine kinase inhibitors with antagonists of A2ARs
might be particularly effective in aged animals. It is hoped
that future work will allow confirming the neuroprotective
efficiency of the combination of these drugs in aged
animals. Also, careful parallel studies will be required to
test if there are unexpected secondary effects that may
appear only in aged animals. In fact, the pharmacokinetics
of most drugs is considerably changed in aged animals, and
some pharmacodynamic characteristics are also modified,
like, for instance, the cardiovascular effects of adenosine in
aged rats [393Y395].
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